ArticleCancer chemotherapy and pharmacology2014

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.

Edward Sausville et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.